Eugene St Clair, MD
Rheumatology · Durham, NCNPI 1851475727
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,780 of the $7,780 with a category attached, or 100.0%. Modernatx, Inc. accounts for 94.9% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $6,817, more than ten times the $400 reported in 2019.
Across 4 payments — averaging $1944.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$7K
- AbbVie$400
Across 4 payments — averaging $111,200 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$443K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Consulting fees$7,780100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 3 | $7,380 |
| AbbVie | 1 | $400 |
How this compares
$7,780 in reported general payments places this provider in the 65th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 46 | $380,451 |
| RinvoqUpadacitinib | 31 | $224,328 |
| Xeljanz XrTofacitinib Citrate | 33 | $223,046 |
| Orencia ClickjectAbatacept | 32 | $196,631 |
| Enbrel SureclickEtanercept | 20 | $173,781 |
| Humira PenAdalimumab | 27 | $170,445 |
| EnbrelEtanercept | 22 | $157,989 |
| OrenciaAbatacept | 17 | $116,783 |
| Actemra ActpenTocilizumab | 14 | $96,518 |
| HumiraAdalimumab | 13 | $84,594 |
| Cevimeline Hcl | 33 | $9,552 |
| Hydroxychloroquine Sulfate | 221 | $9,485 |
| MethotrexateMethotrexate Sodium | 222 | $8,709 |
| Leflunomide | 71 | $7,368 |
| Mycophenolate Mofetil | 26 | $6,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira | $400 | $308,92244 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 210 rheumatology providers in North Carolina.
Other rheumatology in Durham
- Ralph SnydermanDurham$1.3M
- Joseph ShanahanDurham$407K
- Megan ClowseDurham$72K
- Virginia KrausDurham$31K
- Laura SchanbergDurham$20K
- David LeverenzDurham$11K
- Gordon LamCharlotte$2.7M
- Wendy SimmonsWilmington$462K
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.